ALPS Advisors’s BioAtla BCAB Stock Holding History

ALPS Advisors’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-622	Closed	-$83.4K	–	1003
2023 Q1	$83.4K	Sell	622 -6	-1%	-$1.08K	﹤0.01%	1007
2022 Q4	$259K	Buy	+628	New	+$261K	﹤0.01%	948
2022 Q2	–	Sell	-764	Closed	-$191K	–	1037
2022 Q1	$191K	Sell	764 -89	-10%	-$37.2K	﹤0.01%	806
2021 Q4	$837K	Buy	853 +24	+3%	+$30.7K	0.01%	384
2021 Q3	$1.22M	Sell	829 -18	-2%	-$35.1K	0.01%	368
2021 Q2	$1.8M	Buy	+847	New	+$1.91M	0.02%	341

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ALPS Advisors's BCAB Position: Q2 2023 in Review

ALPS Advisors sold out of BioAtla (BCAB) in Q2 2023, closing a stake of 622 shares — an estimated $83.4K sold.

ALPS Advisors first reported a position in BCAB in Q2 2021 and held it in 6 quarters. The position peaked at $1.8M in Q2 2021. 87 funds tracked by Wall St. Rank hold BCAB as of Q2 2023.

ALPS Advisors reported no remaining BioAtla position as of Q2 2023 after selling out during the quarter.
ALPS Advisors sold 622 BioAtla shares in Q2 2023, an estimated $83.4K.
ALPS Advisors first reported a position in BioAtla in Q2 2021 and held it in 6 quarters.
ALPS Advisors's BioAtla position peaked at $1.8M in Q2 2021.
87 funds tracked by Wall St. Rank held BioAtla as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.